The aim of this trial is to measure the safety and effectiveness of different doses of IMMU-130, a new treatment for metastatic colorectal cancer (cancer that has spread beyond the colon or rectum to other areas of the body). The outcomes of this study will include the number of adverse (negative) events that occur during treatment and the follow-up period, the response of the tumor to the treatment (such as change in size), and the time to disease progression (such as growth of a tumor) following treatment.

This study compared two strategies for treating patients with metastatic colorectal cancer (colorectal cancer that has spread to distant sites).

The authors provided information on 4 different types of treatment for patients with colorectal cancer and liver metastases.

This study assessed whether panitumumab is as good as cetuximab for patients with colorectal cancer that is unresponsive to chemotherapy (chemotherapy-refractory colorectal cancer).

This study examined the impact of cancer that has spread to the liver and the lymph nodes surrounding the liver (hepatic hilar lymph node [HLN] metastasis) on patient survival.

This study examined the implications of having a BRAF mutation for patients with colorectal cancer that has spread (metastasized). 

This study examined whether chemotherapy improves the chance of survival for patients with stage II or stage III colon cancer.

The authors reviewed overall survival, progression-free survival and response rate changes with the addition of biologic drugs to chemotherapeutic regimes in metastatic colorectal cancer.

This study examined the impact of emergency presentation on the outcomes of patients with node-negative colorectal cancer undergoing curative surgery.

The authors aimed to review the use of adjuvant chemoradiotherapy with local excision for early stage rectal cancer.